Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice